We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+13.03%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$260M
AUM Growth
+$4.09M
Cap. Flow
-$10.4M
Cap. Flow %
-3.98%
Top 10 Hldgs %
46.09%
Holding
68
New
5
Increased
11
Reduced
10
Closed
14

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$11.8M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$5.56M
3
ABMD
Abiomed Inc
ABMD
+$4.78M
4
INCY icon
Incyte
INCY
+$3.62M
5
XENT
Intersect ENT, Inc
XENT
+$2.94M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$11.9M
2
SAGE
Sage Therapeutics
SAGE
+$4.32M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$4.01M
4
GILD icon
Gilead Sciences
GILD
+$2.9M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$2.73M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
26
Verastem
VSTM
$668M
$3.44M 1.32%
41,667
+8,334
+25% +$510K
BLUE
27
DELISTED
bluebird bio
BLUE
$3.14M 1.2%
1,544
– –
GTHX
28
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.12M 1.2%
72,000
-31,000
-30% -$1.33M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$2.05B
$3.07M 1.18%
36,500
– –
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.03M 1.16%
77,000
– –
SGEN
31
DELISTED
Seagen Inc. Common Stock
SGEN
$2.82M 1.08%
42,500
– –
JAZZ icon
32
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.79M 1.07%
16,200
-2,800
-15% -$458K
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.79M 1.07%
+10,000
New +$1.76M
PBYI icon
34
Puma Biotechnology
PBYI
$477M
$2.73M 1.05%
46,300
+12,300
+36% +$713K
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
$2.61M 1%
322,436
– –
KYNB
36
Kyntra Bio
KYNB
$32.4M
$1.96M 0.75%
1,256
– –
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
$1.95M 0.75%
145,000
– –
MRUS
38
DELISTED
Merus
MRUS
$1.69M 0.65%
75,060
– –
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.6M 0.62%
113,000
+60,000
+113% +$997K
GMED icon
40
Globus Medical
GMED
$11.1B
$1.46M 0.56%
29,000
– –
GWPH
41
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.34M 0.51%
9,600
– –
SUPN icon
42
Supernus Pharmaceuticals
SUPN
$2.57B
$1.25M 0.48%
20,953
– –
HZNP
43
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.14M 0.44%
69,000
– –
PRTK
44
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.05M 0.4%
103,500
– –
RIGL icon
45
Rigel Pharmaceuticals
RIGL
$875M
$1.04M 0.4%
37,000
– –
AERI
46
DELISTED
Aerie Pharmaceuticals
AERI
$998K 0.38%
14,779
– –
ONCE
47
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$992K 0.38%
12,000
– –
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$915K 0.35%
58,600
– –
PTLA
49
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$906K 0.35%
24,000
– –
CRVS icon
50
Corvus Pharmaceuticals
CRVS
$1.24B
$892K 0.34%
+81,341
New +$908K
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2018 Portfolio in Review

As of Q2 2018, International Biotechnology Trust held 68 positions worth $260M, up 1.6% from $256M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

International Biotechnology Trust withdrew a net $10.4M in Q2 2018, closing 14 positions and reducing 10 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $4.01M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Illumina worth $12.6M.

  • International Biotechnology Trust's largest Q2 2018 buy was Illumina: 46,260 shares worth $12.6M.
  • International Biotechnology Trust added most to Incyte in Q2 2018, an estimated $3.62M increase.
  • International Biotechnology Trust's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.9M.
  • International Biotechnology Trust fully exited Clovis Oncology, Inc. in Q2 2018, selling an estimated $4.01M.
  • International Biotechnology Trust's ten largest holdings make up 46% of its $260M portfolio in Q2 2018.
  • International Biotechnology Trust opened 5 new positions and closed 14 in Q2 2018.
  • International Biotechnology Trust's portfolio value rose 1.6% quarter-over-quarter to $260M.

Based on International Biotechnology Trust's 13F filing for Q2 2018, filed 13 Aug 2018.